Zuzana Tóthová (Avtor), Jana Tomc (Avtor), Nataša Debeljak (Avtor), Peter Solár (Avtor)

Povzetek

Erythropoietin (EPO) acts on multiple tissues through its receptor EPOR, a member of a cytokine class I receptor superfamily with pleiotropic effects. The interaction of EPO and EPOR triggers the activation of several signaling pathways that induce erythropoiesis, including JAK2/STAT5, PI3K/AKT, and MAPK. The canonical EPOR/JAK2/STAT5 pathway is a known regulator of differentiation, proliferation, and cell survival of erythroid progenitors. In addition, its role in the protection of other cells, including cancer cells, is under intense investigation. The involvement of EPOR/JAK2/STAT5 in other processes such as mRNA splicing, cytoskeleton reorganization, and cell metabolism has been recently described. The transcriptomics, proteomics, and epigenetic studies reviewed in this article provide a detailed understanding of EPO signalization. Advances in this area of research may be useful for improving the efficacy of EPO therapy in hematologic disorders, as well as in cancer treatment.

Ključne besede

STAT5;erythropoietin receptor;molecular mechanisms;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.02 - Pregledni znanstveni članek
Organizacija: UL MF - Medicinska fakulteta
UDK: 61
COBISS: 70001667 Povezava se bo odprla v novem oknu
ISSN: 1422-0067
Št. ogledov: 237
Št. prenosov: 41
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: STAT5;eritropoetinski receptor;molekularni mehanizmi;
Vrsta dela (COBISS): Članek v reviji
Strani: str. 1-13
Letnik: ǂVol. ǂ22
Zvezek: ǂiss. ǂ13
Čas izdaje: Jun. 2021
DOI: 10.3390/ijms22137109
ID: 14889988